Northland Capital on Medtronic (MDT)
Northland Securities maintained a Market Perform rating on Medtronic, Inc. (NYSE: MDT) and raised its price target to $46.00 (from $44.00).
Commenting on Medtronic's recent fiscal second quarter earnings report, analysts Bruce Jackson said, "CRDM and Core Spine continued to face challenging markets, though the decline in dollar terms seems to be slowing. All of the other business units were up on an as-reported basis."
"FQ2 marks the last quarter of difficult comps arising from the PhysioControl divestiture that was completed one year ago. New products in Coronary (Resolute Integrity DES), Neuromodulation (Restore Sensor, InterStim), and Surgical Technologies (StealthStation) helped those units generategrowth of 14.1%, 7.8% and 15.4%, respectively," added Jackson
For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.
Shares of Medtronic, Inc. closed at $42.66 yesterday, with a 52 week range of $33.21-$44.79.
Commenting on Medtronic's recent fiscal second quarter earnings report, analysts Bruce Jackson said, "CRDM and Core Spine continued to face challenging markets, though the decline in dollar terms seems to be slowing. All of the other business units were up on an as-reported basis."
"FQ2 marks the last quarter of difficult comps arising from the PhysioControl divestiture that was completed one year ago. New products in Coronary (Resolute Integrity DES), Neuromodulation (Restore Sensor, InterStim), and Surgical Technologies (StealthStation) helped those units generategrowth of 14.1%, 7.8% and 15.4%, respectively," added Jackson
For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.
Shares of Medtronic, Inc. closed at $42.66 yesterday, with a 52 week range of $33.21-$44.79.